

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/402,732 12/01/1999		2/01/1999	ALVIN H. SCHMAIER	8820-3	6339	
23973	7590	11/05/2002				
		& REATH	EXAMINER			
ONE LOGAN SQUARE 18TH AND CHERRY STREETS PHILADELPHIA, PA 19103-6996				GUPTA,	GUPTA, ANISH	
				ART UNIT	PAPER NUMBER	
				1654	1654	
				DATE MAILED: 11/05/2002	16	

Please find below and/or attached an Office communication concerning this application or proceeding.

,,	Application No.	Applicant(s)					
Office Action Comment	09/402,732	SCHMAIER ET AL.					
Office Action Summary	Examiner	Art Unit					
	Anish Gupta	1653					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status							
1) Responsive to communication(s) filed on							
2a) ☐ This action is <b>FINAL</b> . 2b) ☐ This	s action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims							
4) Claim(s) 1-28 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) 1-28 are subject to restriction and/or e	lection requirement						
Application Papers							
9) ☐ The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	(PTO-413) Paper No(s) atent Application (PTO-152)					
S. Patent and Trademark Office							

Application/Control Number: 09/402,732

Art Unit: 1654

## **DETAILED ACTION**

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claim s 1-7,10, 11-20, 23, and 24, drawn to linear peptides, classified in class 514, subclass 12+.
  - II. Claims 1-25, drawn to branched peptides, classified in class 514, subclass 12+.
  - III. Claims 26-28, drawn to a method identifying compounds, classified in class 435, subclass 4+.

Note that Group I and Group II contain claims that are common to both groups, such as claim 13. If Applicants elect Group I, then the linear peptides will be examined in the common claims. That if Applicants elect Group I, the peptide (a) and (b) will be examined in, for example, claim 13.

2. The inventions are distinct, each from the other because of the following reasons:

The compounds of Group I and Group II, even though there maybe overlap between class and subclass, are patentably distinct in that they are structurally distinct from one another. For example, the compounds of Group I do not utilize a linker L. The use of the linker gives the compounds of Group II structural distinction over Group I and thus render them patentably distinct.

The method of Group III do no utilize the compounds of Group I or II. The method of Group II is an assay method that will utilized completely different compounds and completely different method steps than Group I or Group II.

3. This application contains claims directed to the following patentably distinct species of the claimed invention:

Application/Control Number: 09/402,732

Art Unit: 1654

For the linear peptides, those in Group I, the compounds corresponding to formula X1-Arg-Pro-Pro-X2

For the branched peptide, those in Group II, the compounds of the formula L-(X1-Arg-Pro-Pro-X2)n.

If Applicants elect either Group I or Group II, Applicants are requested to elect a single disclosed species of either the linear peptide or branched peptide.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-25 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 09/402,732

Art Unit: 1654

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Anish Gupta whose telephone number is (703) 308-4001.

If attempts to

reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback,

can normally be reached on (703)306-3220. The fax phone number of this group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Anish Gupta

BRENDA BRUMBACK
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600